Difference between revisions of "Vinflunine (Javlor)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "Category:Vesicant chemotherapy" to "Category:Vesicant") Tags: mobile edit mobile web edit |
||
Line 13: | Line 13: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
− | [[Category:Vesicant | + | [[Category:Vesicant]] |
[[Category:Microtubule inhibitors]] | [[Category:Microtubule inhibitors]] |
Revision as of 22:33, 7 December 2019
Mechanism of action
From the NCI drug dictionary: A bi-fluorinated derivative of the semi-synthetic vinca alkaloid vinorelbine with antitubulin, antineoplastic, and antiangiogenic activities. Vinflunine inhibits tubulin assembly without any stablization of assembled microtubules at concentrations comparable to those of other vinca alkaloids such as vincristine, vinblastine and vinorelbine; this effect on microtubule dynamics results in cell cycle arrest in mitosis and apoptosis. Compared to other vinca alkaloids, this agent binds weakly to the vinca-binding site, indicating that vinflunine may exhibit reduced neurotoxicity.
Diseases for which it is used
History of FDA approval
Not FDA approved; available in a number of other countries
Also known as
- Brand name: Javlor